Mitotane is the reference drug for the adrenocortical carcinoma treatment; its pharmacological activity seems to depend on drug transformation in two active metabolites: o,p'‐DDE (dichlorodiphenylethene) and o,p'‐DDA (dichlorodiphenylacetate). Mitotane and… Click to show full abstract
Mitotane is the reference drug for the adrenocortical carcinoma treatment; its pharmacological activity seems to depend on drug transformation in two active metabolites: o,p'‐DDE (dichlorodiphenylethene) and o,p'‐DDA (dichlorodiphenylacetate). Mitotane and metabolites are lipophilic agents; thus, they tend to accumulate into adipose tissues (white and brown), which change their prevalence seasonally. Aim of the work was to evaluate mitotane and metabolites plasma levels variation over the year, in adrenocortical cancer patients treated with Lysodren® for at least 6 months.
Journal Title: Journal of Pharmacy and Pharmacology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!